RESEARCH PAPER
Tumor necrosis factor-like weak inducer of apoptosis regulates quadriceps muscle atrophy and fiber-type alteration in a rat model of chronic obstructive pulmonary disease
Jun-Juan Lu 1
,  
Qing Wang 2
,  
Li Hua Xie 1
,  
Qiang Zhang 1
,  
 
 
More details
Hide details
1
Department of Respiratory Medicine, The Third XiangYa Hospital of Central South University, Changsha, People’s Republic of China
2
Department of Respiratory Medicine, Changsha Central Hospital, Changsha, People’s Republic of China
CORRESPONDING AUTHOR
Sheng Hua Sun   

Department of Respiratory Medicine, The Third XiangYa Hospital of Central South University, 138 Tongzipo Road, Changsha, Hunan 410013, People’s Republic of China
Publish date: 2017-11-09
 
Tob. Induc. Dis. 2017;15(November):43
KEYWORDS
ABSTRACT
Background:
In chronic obstructive pulmonary disease (COPD), weakness and muscle mass loss of the quadriceps muscle has been demonstrated to predict survival and mortality rates of patients. Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), as a member of the TNF superfamily, has recently been identified as a key regulator of skeletal muscle wasting and metabolic dysfunction. So our aim was to study the role of TWEAK during quadriceps muscle atrophy and fiber-type transformation in COPD model rats and its possible pathway.

Methods:
Forty-four healthy male adult Wistar rats were randomly divided into two groups: A normal control group (n = 16) and a COPD model group (n = 28). The COPD group was exposed to cigarette smoke for 90 d and injected with porcine pancreatic elastase on day 15, whereas the control group was injected with saline alone. Following treatment, weights of the quadriceps muscles were measured and hematoxylin and eosin staining was performed to identify structural changes in lung and quadriceps muscle tissue. Immunohistochemical staining was also conducted to determine the localization of TWEAK, nuclear factor (NF)-κB, muscle ring finger (MuRF)-1 and proliferator-activated coactivator (PGC)-1a proteins in the quadriceps muscle, and western blotting was used to assess the level of protein expression.

Results:
Compared with controls, COPD model rats exhibited significantly lower quadriceps muscle weight (P < 0.05) accompanied by fiber atrophy and disordered fiber arrangement, a wide gap between adjacent muscle fibers, a significant reduction in nuclear number (P < 0.05) and an uneven size distribution. The proportion of fiber types was also significantly altered (P < 0.05). In addition, TWEAK expression in the quadriceps muscle of COPD model rats was significantly higher than that in control rats (P < 0.05), and was significantly associated with quadriceps atrophy and fiber-type alteration (P < 0.05). Levels of NF-κB, MuRF1 and PGC-1α expression also significantly differed between the two groups (P < 0.05).

Conclusions:
Collectively these data suggest that increased levels of TWEAK may lead to skeletal muscle atrophy and fiber-type alteration, which in turn may be associated with activation of the ubiquitin-proteasome pathway, involving NF-κB, MuRF1 and PGC-1α as potential regulatory factors. These preliminary results in rats suggest that TWEAK may be a therapeutic target for the treatment of muscle atrophy in COPD.

 
REFERENCES (47)
1.
Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):e15–62.
 
2.
Jones SE, Maddocks M, Kon SS, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax. 2015;70(3):213–8.
 
3.
Langen RC, Gosker HR, Remels AH, Schols AM. Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2013;45(10):2245–56.
 
4.
Slot IG, van den Borst B, Hellwig VA, Barreiro E, Schols AM, Gosker HR. The muscle oxidative regulatory response to acute exercise is not impaired in less advanced COPD despite a decreased oxidative phenotype. PLoS One. 2014;9(2):e90150.
 
5.
van den Borst B, Slot IG, Hellwig VA, et al. Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. J Appl Physiol. 2013;114(9):1319–28.
 
6.
Levine S, Bashir MH, Clanton TL, Powers SK, Singhal S. COPD elicits remodeling of the diaphragm and vastus lateralis muscles in humans. J Appl Physiol. 2013;114(9):1235–45.
 
7.
Remels AH, Gosker HR, Verhees KJ, Langen RC, Schols AM. TNF-alpha-induced NF-kappaB activation stimulates skeletal muscle glycolytic metabolism through activation of HIF-1alpha. Endocrinology. 2015;156(5):1770–81.
 
8.
Barreiro E, Peinado VI, Galdiz JB, et al. Cigarette smoke-induced oxidative stress: a role in chronic obstructive pulmonary disease skeletal muscle dysfunction. Am J Respir Crit Care Med. 2010;182(4):477–88.
 
9.
Mercken EM, Hageman GJ, Langen RC, et al. Decreased exercise-induced expression of nuclear factor-κB-regulated genes in muscle of patients with COPD. Chest. 2011;139(2):337–46.
 
10.
Pomies P, Rodriguez J, Blaquiere M, et al. Reduced myotube diameter, atrophic signalling and elevated oxidative stress in cultured satellite cells from COPD patients. J Cell Mol Med. 2015;19(1):175–86.
 
11.
Fermoselle C, Rabinovich R, Ausin P, et al. Does oxidative stress modulate limb muscle atrophy in severe COPD patients. Eur Respir J. 2012;40(4):851–62.
 
12.
Gea J, Agusti A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol. 2013;114(9):1222–34.
 
13.
Puente-Maestu L, Lazaro A, Tejedor A, et al. Effects of exercise on mitochondrial DNA content in skeletal muscle of patients with COPD. Thorax. 2011;66(2):121–7.
 
14.
Gayan-Ramirez G, Decramer M. Mechanisms of striated muscle dysfunction during acute exacerbations of COPD. J Appl Physiol. 2013;114(9):1291–9.
 
15.
Hussain SN, Sandri M. Role of autophagy in COPD skeletal muscle dysfunction. J Appl Physiol. 2013;114(9):1273–81.
 
16.
Puente-Maestu L, Lazaro A, Humanes B. Metabolic derangements in COPD muscle dysfunction. J Appl Physiol. 2013;114(9):1282–90.
 
17.
Sancho-Munoz A, Trampal C, Pascual S, et al. Muscle glucose metabolism in chronic obstructive pulmonary disease patients. Arch Bronconeumol. 2014;50(6):221–7.
 
18.
Tang K, Wagner PD, Breen EC. TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke exposure. J Cell Physiol 2010. 222(2): 320-327.
 
19.
Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. Trends Endocrinol Metab. 2016;27(5):335–47.
 
20.
Mittal A, Bhatnagar S, Kumar A, et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol. 2010;188(6):833–49.
 
21.
Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care. 2010;13(3):225–9.
 
22.
Macpherson PC, Wang X, Goldman D. Myogenin regulates denervation-dependent muscle atrophy in mouse soleus muscle. J Cell Biochem. 2011;112(8):2149–59.
 
23.
Crul T, Testelmans D, Spruit MA, et al. Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. Cell Physiol Biochem. 2010;25(4–5):491–500.
 
24.
Egerman MA, Glass DJ. Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol. 2014;49(1):59–68.
 
25.
Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol. 2005;37(10):1974–84.
 
26.
Enwere EK, Holbrook J, Lejmi-Mrad R, et al. TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci Signal. 2012;5(246):ra75.
 
27.
Girgenrath M, Weng S, Kostek CA, et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 2006;25(24):5826–39.
 
28.
Arany Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev. 2008;18(5):426–34.
 
29.
Hindi SM, Mishra V, Bhatnagar S, et al. Regulatory circuitry of TWEAK-Fn14 system and PGC-1alpha in skeletal muscle atrophy program. FASEB J. 2014;28(3):1398–411.
 
30.
Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25(51):6680–4.
 
31.
Ogura Y, Mishra V, Hindi SM, Kuang S, Kumar A. Proinflammatory cytokine tumor necrosis factor(TNF)-like weak inducer of apoptosis (TWEAK) suppresses satellite cell self-renewal through inversely modulating notch and NF-kappaB signaling pathways. J Biol Chem. 2013;288(49):35159–69.
 
32.
Nesi RT, de Souza PS, Dos SGP, et al. Physical exercise is effective in preventing cigarette smoke-induced pulmonary oxidative response in mice. Int J Chron Obstruct Pulmon Dis. 2016;11:603–10.
 
33.
World Medical Association. American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol Regul Integr Comp Physiol. 2002;283:R281–3.
 
34.
He ZH, Chen P, Chen Y, et al. Comparison between cigarette smoke-induced emphysema and cigarette smoke extract-induced emphysema. Tob Induc Dis. 2015;13(1):6.
 
35.
Padykula HA, Herman E. The specificity of the histochemical method for adenosine triphosphatase. J Histochem Cytochem. 1955;3(3):170–95.
 
36.
Stein JM, Padykula HA. Histochemical classification of individual skeletal muscle fibers of the rat. Am J Anat. 1962;110:103–23.
 
37.
Guth L, Samaha FJ. Qualitative differences between actomyosin ATPase of slow and fast mammalian muscle. Exp Neurol. 1969;25(1):138–52.
 
38.
Vermeeren MA, Creutzberg EC, Schols AM, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med. 2006;100(8):1349–55.
 
39.
Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010;36(1):81–8.
 
40.
Steer J, Norman EM, Afolabi OA, Gibson GJ, Bourke SC. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012;67(2):117–21.
 
41.
Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007;62(2):115–20.
 
42.
Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(6):809–13.
 
43.
Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53–9.
 
44.
Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax. 2007;62(11):944–9.
 
45.
Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev. 2011;244(1):99–114.
 
46.
Tajrishi MM, Zheng TS, Burkly LC, Kumar A. The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease. Cytokine Growth Factor Rev. 2014;25(2):215–25.
 
47.
Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7(5):411–25.
 
 
CITATIONS (3):
1.
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis
Dan Tan, Feng-Mei Pang, Dan Li, Longbo Zhang, Jun Wu, Zhao-Qian Liu, Xi Li, Han Yan
Future Oncology
 
2.
Fluorescent poly(hydroxyurethane): Biocompatibility evaluation and selective detection of Fe(III)
Wan Xu, Bin Liu, Xiaobo Cai, Mohan Zhang, Xing-Hong Zhang, Peilin Yu
Journal of Applied Polymer Science
 
3.
A Novel Murine Chronic Obstructive Pulmonary Disease Model and the Pathogenic Role of MicroRNA-21
Shengyang He, Liqiu Li, Shenghua Sun, Zhengpeng Zeng, Junjuan Lu, Lihua Xie
Frontiers in Physiology
 
eISSN:1617-9625